Promotion of CpG-DNAs, TLRs, CD14 and IL-1R kits, antibodies and proteins

Hycult Biotech Promotion on the 1st quarter for TLR/ CD14, IL-1 R and CpG products

Products	Type of product
CD14	ELISA, mAb
TLR	mAb
IL-R1	mAb
CpG	proteins

Valid from 1st of January 2010 until 31st March 2010.

Special features of the immuno-assays:

HK320	HK206	HK303
Quantification of human sCD14	Quantification of mouse sIL-1 RI	Quantification of human sIL-1 RII
Useful for serum, plasma, urine, breast milk and cell culture supernatant	Useful for serum, plasma and cell culture supernatant	Useful for serum, plasma and cell culture supernatant
Determination within 3.5 hours	Determination within 3.5 hours	Determination within 3.5 hours
Concentration range 8.8 to 100 ng/ml	Concentration range 20 to 5000 pg/m	Concentration range 78 to 5000 pg/ml
Detection level 8.8 ng/ml	Detection level 20 pg/ml	Detection level 78 pg/ml
Working volume 100 µl/well	Working volume 100 µl/well	Working volume 100 µl/well
2 x 96 determinations	2 x 96 determinations	2 x 96 determinations

Elevated levels of sCD14 in:	Elevated levels of L-1R in:	TLRs important mediators for:
Infectious diseases	Inflammation - Peritonitis	Gut diseases
	Inflammation - Colitis	Sepsis

Product name	Quantity	Application	Cat. #.
CD14, Human, mAb 18D11	100 µg	FC FS	HM2224
CD14, Human, mAb MEM-15	100 µg	FC W	HM2060
CD14, Mouse, mAb Sa14-2	100 µg	FC FS IP W	HM1060
CD14, Mouse, mAb Sa14-2, FITC	100 µg	FC W	HM1060F
sCD14, Human, ELISA kit	2 x 96 det.		HK320
CpG-A DNA (ODN 2216), Human/Mouse	200 nmol		HC4037
CpG-B DNA (ODN 2006), Human/ Mouse	200 nmol		HC4039
CpG-B DNA, Rabbit	200 nmol		HC4038
CpG-B DNA, Rat	200 nmol		HC4040
CpG-C DNA (ODN 2395), Human/ Mouse	200 nmol		HC4041
CpG-DNA, Mouse	200 nmol		HC4033
Non CpG-DNA, Human/Mouse	200 nmol		HC4034
Non CpG-DNA, Rabbit	200 nmol		HC4042
IL-1RI, Mouse, mAb D14e3	100 µg	W	HM1025
IL-1RI, Mouse, mAb D1f3	100 µg	FS W	HM1024
IL-1RI, Mouse, mAb Reg20	100 µg	IA IP W	HM1023
IL-1RI, Mouse, mAb Reg21	100 µg	FS IA IP W	HM1022
IL-1RII, Human, mAb 8.5	100 µg	FC IA W	HM2053
IL-1RII, Human, mAb 8.5, FITC	100 µg	FC IA W	HM2053F
IL-1RII, Human, mAb 6G5	100 µg	IA	HM2054
IL-1ra3, Human, mAb 2D11	100 µg	F IA W	HM2055
sIL-1RI, Mouse, ELISA kit	2 x 96 det.		HK206
sIL-1RII, Human, ELISA kit	2 x 96 det.		HK313
TLR1, Human, mAb GD2.F4	100 µg	FC	HM2085
TLR1, Human, mAb GD2.F4, biotinylated	50 µg	FC	HM2086
TLR1, Human, mAb GD2.F4, FITC	100 µg	FC	HM2085F
TLR2, Human, mAb TL2.1	100 µg	F FC FS IA IP P W	HM2064
TLR2, Human, mAb TL2.1, biotinylated	50 µg	F FC IA P W	HM2065
TLR2, Human, mAb TL2.1, FITC	100 µg	F FC IA P W	HM2064F
TLR2, Human, mAb TL2.3	100 µg	FC IA W	HM2066
TLR2, Human, mAb TL2.3, biotinylated	50 µg	FC IA W	HM2067
TLR2, Human, mAb TL2.3, FITC	100 µg	FC	HM2066F
TLR2, Human, mAb TLR2.45	100 µg	IF	HM2220
TLR2, Human, mAb TLR2.45, biotinylated	50 µg	IF	HM2220BT
TLR2, Human, mAb TLR2.45, FITC	100 µg	IF	HM2220F
TLR2, Mouse, mAb 6C2	100 µg	FC IP IF	HM1047
TLR2, Mouse, mAb 6C2, biotinylated	50 µg	FC	HM1048
TLR2, Mouse, mAb 6C2, FITC	100 µg	FC IF	HM1047F
TLR2, Mouse, mAb mT2.4	100 µg	F FC FS IA P	HM1092
TLR2, Mouse, mAb mT2.4, biotinylated	50 µg	F FC IA P	HM1092BT
TLR2, Mouse, mAb mT2.4, FITC	100 µg	F FC IA P	HM1092F
TLR2, Mouse, mAb mT2.7	100 µg	F FC IP	HM1058
TLR2, Mouse, mAb mT2.7, biotinylated	50 µg	F FC	HM1059
TLR2, Mouse, mAb mT2.7, FITC	100 µg	F FC IA	HM1058F
TLR2, Mouse, mAb T2.5	100 µg	F FC FS IP	HM1054
TLR2, Mouse, mAb T2.5, biotinylated	50 µg	F FC	HM1055
TLR2, Mouse, mAb T2.5, FITC	100 µg	F FC	HM1054F
TLR3, Human, mAb TLR3.7	100 µg	FC FS W	HM2096
TLR3, Human, mAb TLR3.7, biotinylated	50 µg	FC W	HM2097
TLR3, Human, mAb TLR3.7, FITC	100 µg	FC W	HM2096F
TLR4, Human, mAb 3C3	100 µg	FC FS	HM2247
TLR4, Human, mAb 3C3, FITC	100 µg	FC	HM2247F
TLR4, Human, mAb HTA125	100 µg	F FC FS IP	HM2068
TLR4, Human, mAb HTA125, biotinylated	50 µg	F FC	HM2069
TLR4, Human, mAb HTA125, FITC	100 µg	FC	HM2068F
TLR4/MD-2, Mouse, mAb MTS510	100 µg	F FC FS IP	HM1029
TLR4/MD-2, Mouse, mAb MTS510, biotinylated	50 µg	F FC	HM1030
TLR4/MD-2, Mouse, mAb MTS510, FITC	100 µg	F FC	HM1029F
TLR4/MD-2, Human, mAb 7E3	100 µg	FC FS	HM2246
TLR4/MD-2, Human, mAb 7E3, biotinylated	50 µg	FC	HM2246BT
TLR4/MD-2, Human, mAb 7E3, FITC	100 µg	FC	HM2246F
TLR6, Human, mAb TLR6.127	100 µg	IF	HM2221
TLR6, Human, mAb TLR6.127, biotinylated	50 µg	IF	HM2221BT
TLR6, Human, mAb TLR6.127, FITC	100 µg	IF	HM2221F
TLR9, Human, mAb 5G5	100 µg	F FC IA W	HM2087
TLR9, Human, mAb 5G5, biotinylated	50 µg	F FC IA W	HM2088
TLR9, Human, mAb 5G5, FITC	100 µg	F FC IA W	HM2087F
TLR9, Mouse, mAb 5G5	100 µg	F FC IA W	HM1042
TLR9, Mouse, mAb 5G5, biotinylated	50 µg	F FC IA W	HM1043
TLR9, Mouse, mAb 5G5, FITC	100 µg	F FC IA W	HM1042F

sCD14
CD14, the 55-kDa glycoprotein known to function as a receptor for LPS, is expressed mainly on the surface of monocytes/macrophages, and polymorphonuclear cells (PMN), the cells responsible for scavenging of LPS and bacteria. Although monocytes and PMN are the main CD14 expressing cells few reports have described CD14 expression on B-cells, mesangial cells and basophils. The plasma protein LBP plays an important role in the LPS-CD14 mediated cell activation. In addition to the function as receptor for LPS, several other functions have been ascribed to CD14; next to the recognition of micro-organisms by the innate immune system CD14 also plays a role in cell-cell interactions.
Besides the membrane bound form of CD14, the soluble form of CD14 (sCD14), which lacks the GPI anchor, is also involved in LPS-induced cell activation. Two forms of sCD14 have been described. An approximately 48 kDa form, derived from monocytes membrane CD14, and a 56 kDa form, speculated to be directly released in plasma or supernatant after processing.
sCD14 affects LPS functioning via several pathways. sCD14 is an intermediate in the transfer of LPS to lipoproteins, resulting into neutralization of LPS. On the contrary, sCD14 facilitates LPS activation of CD14-membrane negative cells like endo- and epithelium. Furthermore, high concentrations of sCD14 were shown to block LPS-induced activation of monocytes. sCD14 thus both enhances and reduces cellular responses to LPS. TLR4 binds directly LPS with the need of soluble CD14 (sCD14).
sCD14 was demonstrated to be present in plasma in levels ranging from 2 - 4 µg/ml and to be enhanced in infectious diseases.

IL-1 R
The IL-1 system includes two agonists (IL-1 alpha and IL-1 beta), converting enzymes, antagonists, two receptors (IL-1RI and IL-1RII) and the IL-1 receptor accessory protein. Interleukin-1 signal is transduced through the type I receptor. In normal serum/plasma of mouse sIL-1RI cannot be detected. After inflammation such as peritonitis and colitis elevated sIL-1RI levels can be found.
The IL-1RII is part of the antagonistic IL-1 mechanism. It is also known as decoy receptor and is a non signaling molecule which functions by capturing IL-1 and preventing it from interacting with the signaling IL-1RI. The decoy IL-1RII, can after binding to IL-1, also recruit the IL-1 receptor accessory protein and thus inhibit by co-receptor competition. A soluble form of IL-1RII exists, which is shed, a process in which matrix metalloproteases have been found to play a role, by various cells including monocytes, polymorphonuclear cells, B cells and fibroblasts. In plasma of healthy individuals soluble IL-1RII (sIL-1RII) levels of approximately 1 - 3 ng/ml are present. In various inflammatory diseases this level is enhanced up to 50 ng/ml.
As investigated so far all functional characterized TLR signal via the TLR/IL-1 receptor (IL-1R) pathway where recruitment of MyD88 seems to be essential.

TLRs
Toll-like receptors (TLR) are highly conserved throughout evolution and have been implicated in the innate defense to many pathogens. In mammals, TLR identified as type I transmembrane signaling receptors with pattern recognition capabilities, have been implicated in the innate host defense to pathogens.
The family of TLR make macrophages, mast cells and immature dendritic cells able to distinguish between apoptotic particles as a result of normal tissue turnover and particles that are indicative of infection. Stimulation of these cells through the TLRs initiates the inflammatory response. TLRs recognize particles of the microbial cell walls or pathogen-specific nucleic acids. Examples of ligands that are recognized by the TLRs are LPS, CpG-DNAs and dsRNA.

Last modified: 13/01/2010 14:38